Renal cell carcinoma (rcc)

Show results for

Unknown (3052)
Genomics (452)
Transcriptomics (446)
Proteomics (48)
Clinical (25)
Other (16)
Metabolomics (15)
Methylation profiling (8)
Genomic (4)
Models (1)

Organisms

Homo sapiens (604)
Mus musculus (39)
Rattus norvegicus (8)
Emiliania huxleyi (4)
Drosophila melanogaster (3)
synthetic construct (2)
Anopheles merus (1)
Macaca mulatta (1)
Bos indicus (1)
Betapolyomavirus hominis (1)
Betapolyomavirus macacae (1)
Human alphaherpesvirus 1 (1)
Human alphaherpesvirus 2 (1)
Human betaherpesvirus 5 (1)
Human gammaherpesvirus 8 (1)
Human immunodeficiency virus 1 (1)
JC polyomavirus (1)
Merkel cell polyomavirus (1)
Murid betaherpesvirus 1 (1)
Murid gammaherpesvirus 4 (1)
Mus musculus cytomegalovirus 2 (1)
human gammaherpesvirus 4 (1)

Organisms

Homo sapiens (234)
Mus musculus (19)
Rattus norvegicus (4)
unidentified (3)
Drosophila melanogaster (1)

Repository

biostudies-arrayexpress (308)
ENA (303)
geo (222)
EGA (87)
pride (32)
MetaboLights (15)
MassIVE (7)
jPOST (5)
dbGaP (4)
iProX (3)
EVA (2)
BioModels (1)
PeptideAtlas (1)

Tissue

Kidney (12)
Cell culture (8)
Epithelial cell (3)
Urine (2)
Others (1)
B cell (1)
Bladder (1)
Blood plasma (1)
Cell (1)
Cell line cell (1)
Epithelial cell of proximal tubule (1)
Kidney cell (1)
Kidney epithelial cell (1)
Malignant cell (1)
Monocyte (1)
Ovarian serous carcinoma cell (1)
Ovarian surface epithelial cell (1)
Ovary (1)
Permanent cell line cell (1)
RCC 786-O cell (1)
Renal cell carcinoma cell (1)
Renal cell carcinoma cell line (1)
Renal principal cell (1)
Urinary bladder cancer cell (1)

Disease

Renal cell carcinoma (11)
Carcinoma (7)
Carcinoma, Renal Cell (5)
Renal clear cell carcinoma (4)
Normal (3)
Papillary renal cell carcinoma (3)
Kidney cancer (3)
Malignant neoplasm of ovary (3)
Urinary bladder cancer (3)
Lung Neoplasms (2)
Neoplasms (2)
Kidney Clear Cell Carcinoma (1)
Normal renal cortex (1)
Clear cell renal cell carcinoma (1)
Tumour (1)
Melanoma (1)
Carcinoma (1)
Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC). (1)
Carcinoma, Ovarian Epithelial (1)
Colorectal Neoplasms (1)
Glioblastoma (1)
Liver Neoplasms (1)
Lymphoma (1)
Neoplasms by Site (1)
Renal cell cancer (1)
Sarcoma (1)
Cholangiocarcinoma (1)
Ovarian cancer (1)
Pancreatic cancer (1)
Prostate cancer (1)

Technology Type

Mass Spectrometry (32)
Shotgun proteomics (15)
Mass spectrometry (10)
Affinity purification coupled with mass spectrometry proteomics (6)
Mass spectrometry assay (5)
Bottom-up proteomics (4)
Immunopeptidomics (3)
Illumina HiSeq 2500 (2)
Illumina HiSeq 2500, ILLUMINA (2)
Data-dependent acquisition (2)
Data-independent acquisition (2)
Gel-based experiment (2)
SWATH MS (2)
Top-down proteomics (2)
GeneChip HTA 2.0 (1)
Illumina Genome Analyzer II (1)
Illumina HiSeq 2000 (1)
Illumina HiSeq 2000, ILLUMINA (1)
Illumina HumanCNV370, Illumina HumanHap 300 v2 Duo, Taqman and sequencing, Illumina Human660W-Quad (1)
Affinity proteomics (1)

Instrument Platform

Illumina NovaSeq 6000 (6)
Illumina Genome Analyzer IIx (3)
Illumina HiSeq 2500 (3)
Illumina HiSeq 4000 (3)
NextSeq 500 (3)
Illumina HiSeq 2000 (2)
- (2)
Q Exactive (2)
NanoString nCounter (1)
Genomics Core Shared Resources at Augusta University (RRID: SCR_026483) (1)
RNeasy Mini Kit (Qiagen) (1)
GentleMACS Octo Dissociator with Heaters (Miltenyi Biotec, Cat. No. 130-096-427) together with the Human Tumor Dissociation Kit (Miltenyi Biotec, Cat. No. 130-095-929), (1)
NCounter Prep Station & Digital Analyzer (1)
NanoString (1)
TapeStation (1)
Element AVITI (1)
NCounter Digital Analyzer (1)
NCounter Prep Station (1)
NanoDrop ND-100 (1)
Generic (1)
Affymetrix GeneChip Scanner (1)
Computer (1)
Maxwell 16, Promega (1)
HiScan, Illumina (1)
HiSeq 2000 (1)
Affymetrix Gene Titan (1)
Gene Titan (1)
Affymetrix GeneChip Scanner 3000 (1)
N/A (1)
Illumina HiSeq 1500 (1)

Publication Date

2016 (59)
2015 (53)
2012 (52)
2025 (47)
2010 (44)
2013 (42)
2014 (40)
2026 (39)
2024 (28)
2011 (24)
2022 (23)
2021 (22)
2008 (22)
2020 (17)
2023 (16)
2019 (15)
2017 (14)
2009 (12)
2018 (9)
2007 (6)
2006 (3)
2003 (3)
2005 (1)
2004 (1)
2001 (1)

UNIPROT ID/AC

A0A024RC46 (1)
A2BFH1 (1)
A4D110 (1)
A5A3E0 (1)
A6NHL2 (1)
A6NNZ2 (1)
B1AK88 (1)
B2RPK0 (1)
B2RXF3 (1)
B3KML9 (1)
B3KT93 (1)
B4DHB3 (1)
B4DL86 (1)
B4DPR2 (1)
B4DRV9 (1)
B4DY08 (1)
B4E3A4 (1)
B8ZZ43 (1)
B8ZZQ6 (1)
B9VP19 (1)
C9JM50 (1)
C9JRZ8 (1)
C9JSZ1 (1)
D3DPU2 (1)
E7EX29 (1)
E9PAV3 (1)
E9PFP8 (1)
E9PGC8 (1)
E9PKG0 (1)
F8VRH0 (1)

ENSEMBL ID

ENSG00000170477 (1)

CHEBI ID

CHEBI:15603 (3)
CHEBI:15891 (3)
CHEBI:16919 (3)
CHEBI:136085 (2)
CHEBI:15318 (2)
CHEBI:15756 (2)
CHEBI:15843 (2)
CHEBI:16015 (2)
CHEBI:16196 (2)
CHEBI:16359 (2)
CHEBI:16552 (2)
CHEBI:16708 (2)
CHEBI:16737 (2)
CHEBI:16828 (2)
CHEBI:17295 (2)
CHEBI:17351 (2)
CHEBI:17368 (2)
CHEBI:17929 (2)
CHEBI:18132 (2)
CHEBI:26806 (2)
CHEBI:28792 (2)
CHEBI:28867 (2)
CHEBI:30805 (2)
CHEBI:39448 (2)
CHEBI:4178 (2)
CHEBI:44897 (2)
CHEBI:48430 (2)
CHEBI:6650 (2)
CHEBI:72998 (2)
CHEBI:73025 (2)

Metabolite Name

Adenine (3)
Linoleic acid (3)
2-Hydroxymyristic acid (2)
Adenosine (2)
Alanine (2)
Aspartate (2)
Butyrylcarnitine (2)
Cholic acid (2)
Creatine (2)
Guanine (2)
Guanosine (2)
L-Leucine (2)
N1-Acetylspermine (2)
Oleic acid (2)
PC(16:0/0:0) (2)
PC(18:2/18:2) (2)
Palmitic acid (2)
Taurine (2)
Uric acid (2)
Xanthosine (2)
(+)-.gamma.-Tocopherol (1)
(+)-2-Hydroxyisocaproic acid (1)
(+)-Abscisic acid (1)
(-)-Catechin (1)
(-)-Chimonanthine (1)
(-)-Epiafzelechin 3-gallate (1)
(-)-N-Acetylneuraminic acid (1)
(-)-Quinic acid (1)
(-)-Riboflavin (1)
(.+/-.)-11-Nor-.DELTA.9-tetrahydrocannabinol-9-carboxylic acid (1)

First Public Date

2014 (63)
2025 (48)
2024 (39)
2026 (37)
2022 (21)
2021 (16)
2017 (16)
2015 (14)
2023 (13)
2019 (11)
2018 (9)
2020 (7)
2016 (5)
2013 (4)

Modelling Approach

Ordinary differential equation model (1)

Study status

Completed (11)
Terminated (6)
Active, not recruiting (4)
Recruiting (4)

Lab affiliation

Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, OncoProteomics Laboratory, Amsterdam, Netherlands (2)
Dept. Oncology-Pathology, Scilifelab, Karolinska Institutet, Sweden (2)
Kyungpook national university (2)
Masaryk University, Faculty of Science (2)
School of Medicine, Fu Jen Catholic University, New Taipei, Taiwan (2)
Assistant professor, Biochemistry and Molecular Biology, Johns Hopkin Bloomberg Schools of Public Health, USA. (1)
Center of Excellence in Systems Biology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand (1)
Clinical Proteomics, Mosaiques Diagnostics GmbH (1)
Department of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA; Department of Biophysics and Biophysical Chemistry, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA. (1)
Department of Life Sciences, University of Mdoena and Reggio Emilia (1)
Department of Oncology, The Johns Hopkins University School of Medicine's Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA (1)
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada (1)
Department of Pathology and Molecular Pathology, University Hospital Zürich and University of Zürich, Zürich, Switzerland (1)
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA (1)
Department of Pharmacology & Neuroscience UNT Health Science Center Fort Worth, TX, USA (1)
Department of Translational Medical Sciences, School of Medicine, Texas A&M University, Houston, TX, USA (1)
Dept. Oncology-Pathology, Scilifelab, Karolinska Institutet, Stockholm, Sweden (1)
Koc University (1)
Molecular Proteomics Laboratory, Heinrich Heine University Düsseldorf, Düsseldorf, GermanyMolecular Proteomics Laboratory, Heinrich Heine University Düsseldorf, Düsseldorf, Germany (1)
Proteomics, Metabolomics & Mass Spectrometry Laboratory, Institute for the Animal Production System in the Mediterranean Environment (ISPAAM), National Research Council, Piazzale Enrico Fermi 1, 80055 Portici (NA), Italy (1)
Purdue University (1)
Research Center of Basic Medical Sciences, Tianjin Medical University, China (1)
School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea (1)
Sir run run shaw hospital (1)
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy (1)
State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Xiamen, Fujian 361102, China (1)
The Third Medical Center, Chinese PLA General Hospital (1)

Keyword

RCC (9)
Pembrolizumab (8)
CRC (5)
TNBC (5)
SCCHN (4)
HCC (3)
Immunotherapy (3)
Nivolumab (3)
PDR001 (3)
Paclitaxel (3)
Spartalizumab (3)
A2aR (2)
Advanced (2)
Endometrial (2)
Everolimus (2)
GEJ (2)
Gemcitabine (2)
HNSCC (2)
Kidney Cancer (2)
NIR178 (2)
Ovarian (2)
PD-1 (2)
Sorafenib (2)
Tumor Metabolism (2)
Adenosine (1)
Adrenocortical carcinoma (ACC) (1)
Advanced solid malignancies (1)
Anti PD-L1 (1)
Anti-PD-1 (1)
Antibody (1)

IsPrivate

False (1)

Submitter Keywords

Immuno-oncology (1)

Study type

Transcription profiling by array (211)
Interventional (23)
Comparative genomic hybridization by array (22)
RNA-seq of coding RNA (19)
Genotyping by array (10)
ChIP-seq (10)
Methylation profiling by array (6)
Other (5)
Unknown experiment type (4)
RNA-seq of non coding RNA (4)
RNA-seq of coding RNA from single cells (3)
Cell line - High-throughput sequencing (2)
Observational (2)
Transcription profiling by SAGE (1)
ChIP-chip by tiling array (1)
Human - High-throughput sequencing (1)
Human - One-color microarray (1)
RNAi profiling by array (1)
Transcription profiling by RT-PCR (1)
MicroRNA profiling by high throughput sequencing (1)
Spatial transcriptomics by high-throughput sequencing (1)
Single nucleus RNA sequencing (1)
MicroRNA profiling by array (1)
Genotyping by high throughput sequencing (1)
Methylation profiling by high throughput sequencing (1)

Release Date

2021 (371)
2022 (367)
2023 (340)
2020 (298)
2025 (283)
2024 (268)
2019 (201)
2016 (192)
2017 (173)
2018 (158)
2015 (154)
2014 (120)
2013 (108)
2012 (79)
2010 (66)
2011 (54)
2026 (39)
2008 (28)
2009 (25)
2007 (10)
2006 (8)
2005 (5)
2003 (5)
2001 (3)
2004 (2)
2000 (2)
1998 (1)

Location

United States (24)
Spain (10)
United Kingdom (10)
Australia (7)
France (7)
Italy (7)
Canada (6)
Germany (6)
Netherlands (6)
South Korea (5)
Taiwan (5)
Asia except Japan (4)
Belgium (4)
Europe (4)
Japan (4)
North America (4)
Singapore (4)
Argentina (3)
Chile (3)
Czechia (3)
Brazil (2)
Mexico (2)
Poland (2)
Austria (1)
China (1)
Hong Kong (1)
Israel (1)
New Zealand (1)
Norway (1)
Oceania (1)

Previous page
1 / 407
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 407
Next page

Sort by:

Relevance

Page size

Postoperative Metabolic Phenoreversion in Clear Cell Renal Cell Carcinoma

The ultimate goal of surgical treatment in cancer is to remove the tumor mass for restoring a healthy state. A 16-lipid panel that discriminated healthy controls from clear cell renal cell carcinoma (ccRCC) patients in a prior study was evaluated in the present work in paired-serum samples collec...

2023-01-02 | MTBLS3838 | MetaboLights

Urinary multi-omics reveal non-invasive diagnostic biomarkers in clear cell renal cell carcinoma (Lipidomics)

Clear cell renal cell carcinoma (ccRCC) is the most common kidney malignancy. Yet, no rapid, non-invasive biomarkers are available for diagnosis or screening. Urine represents an ideal analyte matrix due to its accessibility, low invasiveness, longitudinal sampling and the kidney’s central role i...

2026-07-15 | MTBLS14671 | MetaboLights

Urinary multi-omics reveal non-invasive diagnostic biomarkers in clear cell renal cell carcinoma

2026-08-16 | MTBLS12025 | MetaboLights

Mass Spectrometry-Based Metabolic Fingerprinting Contributes to Unveil the Role of RSUME in Renal Cell Carcinoma Cell Metabolism

Clear cell renal cell carcinoma (ccRCC) is a heterogeneous disease with 50-80% patients exhibiting mutations in the von Hippel-Lindau (VHL) gene. RSUME (RWD domain (termed after three major RWD-containing proteins: RING finger-containing proteins, WD-repeat-containing proteins, and yeast DEAD (DEXD)...

2021-10-06 | MTBLS1935 | MetaboLights

Distinct succinate modifying products are clinically diagnostic and prognostic biomarkers for fumarate hydratase deficient renal cell carcinoma

Germline or somatic loss-of-function of fumarate hydratase (FH) predisposes patients to an aggressive form of renal cell carcinoma (RCC). Since other than tumor resection, there is no effective therapy for FH-deficient RCC, a competent method for early diagnosis and for early detection of recurre...

2022-08-12 | MTBLS3628 | MetaboLights

Coupled Mass-Spectrometry-Based Lipidomics Machine Learning Approach for Early Detection of Clear Cell Renal Cell Carcinoma

A discovery-based lipid profiling study of serum samples from a cohort that included patients with clear cell Renal Cell Carcinoma (ccRCC) stage I, II, III, and IV (n=112) and controls (n=52) was performed using ultraperformance liquid chromatography coupled to quadrupole-time-of-flight mass spec...

2020-11-20 | MTBLS1839 | MetaboLights

Genome-wide gene expression profiles of clear cell renal cell carcinoma; Identification of molecular targets for treatment of renal cell carcinoma

In order to clarify the molecular mechanism involved in renal carcinogenesis, and identify molecular targets for diagnosis and treatment, we analyzed genome-wide gene expression profiles of 15 surgical specimens of clear cell renal cell carcinoma (RCC), compared to normal renal cortex, using a combi...

ORGANISM(S): Homo sapiens

2012-07-15 | E-GEOD-39364 | biostudies-arrayexpress

DNA Copy-Number Alterations in clear-cell Renal Cell Carcinoma (ccRCC) Tumors and Tumorgrafts for samples deficient in BAP1 or PBRM1

Renal cell carcinoma (RCC) exhibits some unusual features and genes commonly mutated in cancer are rarely mutated in clear-cell RCC (ccRCC), the most common type. The most prevalent genetic alteration in ccRCC is the inactivation of the tumor suppressor gene VHL. Using whole-genome and exome sequenc...

ORGANISM(S): Homo sapiens

2012-06-09 | E-GEOD-25540 | biostudies-arrayexpress

microRNA Profiling in Metastatic Renal Cell Carcinoma

We performed a microRNA (miRNA) microarray on 10 metastatic RCC tumors and compared differential miRNA expresison to 19 primary clear cell renal cell carcinomas (ccRCC). We found there were 65 significantly dysregulated miRNAs; 9 miRNAs were significantly upregulated and 56 miRNAs were significantly...

ORGANISM(S): Homo sapiens

2012-08-13 | E-GEOD-39440 | biostudies-arrayexpress

Renal Cell Carcinoma (RCC) tumorgrafts exhibit similar gene expression profiling to corresponding primary tumors

Primary tumors of Renal Cell Carcinoma (RCC) were implanted orthotopically into mice and their gene expression profiling was compared to their corresponding tumors using Affymetrix Human Genome U133 Plus 2.0 arrays.

ORGANISM(S): Homo sapiens

2012-06-05 | E-MTAB-1050 | biostudies-arrayexpress

Previous page
1 / 407
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 407
Next page

Sort by:

Relevance

Page size

4067 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

UNIPROT ID/AC

ENSEMBL ID

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Submitter Keywords

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets